Post-translational modifications of proteins, mainly aberrant glycosylation [5], represent a promising biomarker, potentially integrating both of these specificities with a typical tissue-specific marker—PSA (prostate-specific antigen) in the case of prostate cancer (PCa) [6,7]. This evidence concerns the gene KLK3 and prostate cancer.